Partnerships and Progress: Acorai’s Journey to Better Heart Health

Imagine a world where heart failure patients can have their cardiac and vascular pressures monitored without undergoing invasive procedures; this is the vision Acorai is turning into reality. Founded in 2019, the Swedish startup has developed a non-invasive “intracardiac pressure” (blood flow in the heart chambers and through the lungs) device designed to replace invasive procedures like catheterization. The device leverages a proprietary sensing system combined with advanced machine learning algorithms to provide accurate, real-time heart pressure readings through the patient's skin. These sensors pick up different signals from the patient's chest, including vibrations, sounds, blood flow, and electrical activity of the heart. The data collected is then interpreted by machine learning algorithms to provide accurate readings of intracardiac pressure. 

Matthew Mace, Acorai’s Chief Science Officer, explains the uniqueness of their approach: "We have integrated various sensor technologies to develop a robust and non-invasive solution. This will allow us to present clinically meaningful data directly to clinicians, enabling them to make informed decisions about patient care." 

The Importance of Collaboration 

Collaboration is at the heart of Acorai’s progress. The company has formed strategic partnerships with major medical organizations such as the American Heart Association (AHA) and has the goal of advance collaboration with the American College of Cardiology (ACC) and the Heart Failure Society of America (HFSA). These collaborations will be essential for validating and advancing Acorai's technology and bringing the technology into real-life use.  

Mace emphasizes, "Innovation in our field doesn’t happen in isolation. It's driven by partnerships between industry and medical professionals. Our engagements with organizations like these are about understanding clinical needs and generating the necessary evidence to demonstrate meaningful outcomes." 

Acorai is also working closely with regulators and healthcare providers to navigate the complex landscape of medical device approval and reimbursement. This includes engaging with the U.S. Food and Drug Administration (FDA) and their partners at the Centers for Medicare & Medicaid Services (CMS) to ensure their device meets the necessary criteria for approval, coverage, and payment in the U.S. healthcare system. 

Though the path to regulatory approval is complex, Acorai is well-prepared to navigate it. The company has been designated a "Breakthrough Device" by the FDA, which provides a streamlined pathway for innovative medical devices. This designation, awarded in August 2023, acknowledges the potential of Acorai's device to improve heart failure management significantly. 

Clinical Progress and Studies 

Acorai has also made significant strides in its clinical research. The CAPTURE-HF study, a global clinical trial involving 1,200 patients, aims to validate the performance of Acorai’s device. This study is crucial for demonstrating the device’s accuracy and reliability in a real-world clinical setting. This is one of the largest studies of its type to ever be performed, and remarkably, the first 1200 enrollment took the start-up less than 7 months to complete. In addition to CAPTURE-HF, Acorai has initiated an investigative study in the UK to explore the prognostic value of their measurements. 

The company’s focus is now on completing these studies and planning the next phase of clinical testing. "We are at an inflection point," says Mace. "Having completed major phases of our trials, we are now engaging with our clinical partners to determine the next steps and ensure our studies provide maximum value to stakeholders." 

Economic Impact 

Heart failure treatment is notably expensive, with hospitalizations being the primary cost driver. Mace emphasizes that 80% of these costs are associated with inpatient stays. Acorai’s device aims to reduce these costs by enabling more effective outpatient treatment and reducing the need for prolonged or repeated hospital admissions. 

The economic rationale behind Acorai’s approach is compelling. In the United States, heart failure accounts for approximately 27% of all hospital readmissions, making it the most burdensome disease for inpatient care. Faster and more precise treatment can extend lives and reduce the frequency of hospital readmissions. This in turn frees up valuable resources and beds for other critical treatments, such as heart valve replacements or defibrillator installations.  

Healthcare Accessibility and Equity 

Aside from economic effects, Acorai is also devoted to enhancing healthcare accessible and tackling health equality concerns. Mace emphasizes the need of providing innovative medical technology to all patients, regardless of socioeconomic background. By utilizing Acorai's non-invasive technology, hospitals might provide diagnostic and monitoring services to a bigger, more diversified patient group. 

Outreach initiatives are an important part of this endeavor. Acorai's technology may be incorporated into mobile clinics and community health programs, providing vital heart failure diagnoses to patients who might otherwise go untreated. Acorai bridges the healthcare access gap by delivering an accessible and reliable diagnostic tool, ensuring that more patients receive the care they require. 

Looking Ahead 

Dr. Timothy Fendler, a renowned cardiologist, has been particularly vocal about the promise of Acorai’s device. In a recent press release, he stated, “Acorai may have the potential to change the game in diagnostics, monitoring, and treatment of patients with heart failure.” This strong endorsement highlights the transformative potential of Acorai’s technology in providing accurate, non-invasive intracardiac pressure measurements. 

In addition to individual endorsements, Acorai has established partnerships with leading institutions like Mayo Clinic and Cedars-Sinai. These collaborations not only provide access to critical clinical data but also offer a platform for further validation and refinement of the technology. "Working with top-tier institutions allows us to leverage their expertise and ensure our device meets the highest standards of clinical efficacy," says Mace. 

As Acorai prepares for market entry and continues to build strong relationships with key stakeholders, their commitment to collaboration positions them as future leaders in the healthcare space.